X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUN PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUN PHARMA DISHMAN PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.1 25.6 97.9% View Chart
P/BV x 3.3 3.7 89.4% View Chart
Dividend Yield % 0.7 0.6 108.2%  

Financials

 DISHMAN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUN PHARMA
Mar-17
DISHMAN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs374842 44.5%   
Low Rs129572 22.5%   
Sales per share (Unadj.) Rs197.8131.6 150.3%  
Earnings per share (Unadj.) Rs21.232.7 64.8%  
Cash flow per share (Unadj.) Rs34.738.0 91.4%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.80.5 160.6%  
Book value per share (Unadj.) Rs179.9152.7 117.8%  
Shares outstanding (eoy) m80.692,399.26 3.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.4 23.7%   
Avg P/E ratio x11.921.6 54.9%  
P/CF ratio (eoy) x7.218.6 38.9%  
Price / Book Value ratio x1.44.6 30.2%  
Dividend payout %9.410.7 88.1%   
Avg Mkt Cap Rs m20,3061,696,877 1.2%   
No. of employees `0000.817.5 4.7%   
Total wages/salary Rs m5,35549,023 10.9%   
Avg. sales/employee Rs Th19,252.718,028.3 106.8%   
Avg. wages/employee Rs Th6,459.52,798.8 230.8%   
Avg. net profit/employee Rs Th2,064.14,479.5 46.1%   
INCOME DATA
Net Sales Rs m15,961315,784 5.1%  
Other income Rs m2656,232 4.3%   
Total revenues Rs m16,226322,016 5.0%   
Gross profit Rs m4,103100,893 4.1%  
Depreciation Rs m1,09112,648 8.6%   
Interest Rs m9443,998 23.6%   
Profit before tax Rs m2,33490,479 2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m199 1.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62412,116 5.1%   
Profit after tax Rs m1,71178,462 2.2%  
Gross profit margin %25.731.9 80.5%  
Effective tax rate %26.713.4 199.6%   
Net profit margin %10.724.8 43.1%  
BALANCE SHEET DATA
Current assets Rs m11,018329,537 3.3%   
Current liabilities Rs m9,517178,870 5.3%   
Net working cap to sales %9.447.7 19.7%  
Current ratio x1.21.8 62.8%  
Inventory Days Days11079 139.9%  
Debtors Days Days3583 41.8%  
Net fixed assets Rs m16,304204,766 8.0%   
Share capital Rs m1612,399 6.7%   
"Free" reserves Rs m12,907363,997 3.5%   
Net worth Rs m14,516366,397 4.0%   
Long term debt Rs m4,18914,361 29.2%   
Total assets Rs m29,805614,102 4.9%  
Interest coverage x3.523.6 14.7%   
Debt to equity ratio x0.30 736.4%  
Sales to assets ratio x0.50.5 104.1%   
Return on assets %8.913.4 66.4%  
Return on equity %11.821.4 55.0%  
Return on capital %17.524.8 70.6%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95244,118 11.2%   
Fx outflow Rs m69724,484 2.8%   
Net fx Rs m4,25519,634 21.7%   
CASH FLOW
From Operations Rs m2,78670,822 3.9%  
From Investments Rs m-1,529-42,216 3.6%  
From Financial Activity Rs m-941-22,854 4.1%  
Net Cashflow Rs m3166,107 5.2%  

Share Holding

Indian Promoters % 61.4 63.7 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.1 72.1%  
FIIs % 12.7 23.0 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.3 266.3%  
Shareholders   46,261 133,026 34.8%  
Pledged promoter(s) holding % 35.8 0.5 6,747.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - NOVARTIS COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS